

Pharmacological Review on *Astragalus membranaceus*: Chinese Traditional Herb

Abu Md Ashif Ikbal^{1,*}, Amlanjyoti Rajkhowa¹, Bikash Debnath^{1,2,*}, Waikhom Somraj Singh^{1,3}, Kuntal Manna^{1,*}, Bedanta Bhattacharjee⁴, Tanmoy Das⁵, Sanchari Goswami^{1,6}

Abu Md Ashif Ikbal^{1,*}, Amlanjyoti Rajkhowa¹, Bikash Debnath^{1,2,*}, Waikhom Somraj Singh^{1,3}, Kuntal Manna^{1,*}, Bedanta Bhattacharjee⁴, Tanmoy Das⁵, Sanchari Goswami^{1,6}

¹Department of Pharmacy, Tripura University (A Central University), Suryamaninagar, Agartala, Tripura, INDIA.

²Department of Pharmaceutics, Regional Institute of Pharmaceutical Science and Technology, Abhaynagar, Agartala, Tripura, INDIA.

³Department of Allied Health Sciences, The ICFAI University, Kamalghat, Mohanpur, Agartala, Tripura, INDIA.

⁴Girijananda Chowdhury, Institute of Pharmaceutical Sciences, Tezpur, Assam, INDIA.

⁵Department of Pharmaceutical Science, Assam University (A Central University), Silchar, Assam, INDIA.

⁶Department of Pharmacology, Bharat Institute of Technology, Ibrahimpattanam, Ranga Reddy, Telangana, INDIA.

Correspondence

B Debnath,

¹Natural cum Advance Synthetic Lab., Department of Pharmacy, Tripura University (A Central University), Suryamaninagar-799 022, Agartala, Tripura, INDIA.

²Department of Pharmaceutics, Regional Institute of Pharmaceutical Science and Technology, Agartala-799 005, Tripura, INDIA. E-mail: bikashrips2014@gmail.com

³Abu Md Ashif Ikbal

¹Natural cum Advance Synthetic Lab., Department of Pharmacy, Tripura University (A Central University), Agartala-799 022, Tripura, INDIA.

Email id: abumd97@gmail.com

⁴Dr. K Manna

¹Natural cum Advance Synthetic Lab., Department of Pharmacy, Tripura University (A Central University), Agartala-799 022, Tripura, INDIA.

Email id: k_manna2002@yahoo.com

History

- Submission Date: 12-02-2022;
- Review completed: 18-03-2022;
- Accepted Date: 24-04-2022

DOI : 10.5530/phrev.2022.16.13

Article Available online

<http://www.phcogrev.com/v16/f32>

Copyright

© 2022 Phcog.Net. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

ABSTRACT

Astragalus membranaceus is a Chinese medicinal plant belonging to the family Leguminosae. This plant is actively used in traditional Chinese medicine for its diverse therapeutic application. The plant contains various active phytochemicals that produce various pharmacological activities. From the literature review, the essential pharmacological activities of *Astragalus membranaceus* are reduce oxidative stress, neuroprotective, antiviral, anti-cancer, immunomodulatory, vascular protective, and antimicrobial activities. In this review, we summarize the pharmacological activities of *Astragalus membranaceus* with the proper mechanism of action.

Keywords: Phytoconstituents, Neuroprotective, Antiviral, Anti-neoplastic, Immunodulatory agent, Alzheimer, Cardioprotective.

INTRODUCTION

Nowadays, traditional Chinese medicine is an important complementary or alternative drug delivery system. Traditional Chinese medicine treatments are based on a holistic approach.^[1] *Astragalus membranaceus* (Fisch.) Bunge is a traditional Chinese medicinal herb belonging to the family Leguminosae. The plant is 50–150 cm high, with a straight, long, cylindrical root, measuring 20–50 cm. It consists of an erect type of stem.^[2] The root of *Astragalus membranaceus* is known as Huangqi in the Chinese language. The herb is well-known for its various pharmacological activities like neuroprotective, antiviral, anti-cancer, immunomodulatory, vascular protective, and antimicrobial actions.^[3] It is also used as a vital-energy tonifying agent. Several herbal formulations are prepared to use the different parts of this Chinese herb. The literature has revealed that the polysaccharide fractions of *Astragalus membranaceus* modulation of immune functions of the human body. The native of *Astragalus membranaceus* is Northern China and the elevated regions, including the provinces of Inner Mongolia, Shanxi, Gansu, and Heilungkiang.^[4]

The essential medicinal parts of *Astragalus membranaceus* is four-to seven-year-old dried root. Worldwide more than 2000 species of *Astragalus* are available. *Astragalus membranaceus* (Fisch.) Bunge is mostly used as a Chinese traditional medicine.^[3] *Astragalus membranaceus* consist of a complex chemical profile. Identified major active phytochemicals are triterpene saponins, flavonoids,

and polysaccharides. Other phytoconstituents are triterpene saponins, flavonoids, and polysaccharides. Other components found in the herb include phytosterols, L-canavanine, sterols, betaine, choline, (+)-lariciresinol, (-)-syringaresinol, lupenone, 3-hydroxy-2-methylpyridine, amino acids, bifendatatum, and coumarin. Identified essential minerals are zinc, iron, copper, magnesium, manganese, calcium, sodium, and potassium.^[5] The aim of this review is a summarization of pharmacological activities of *Astragalus membranaceus*.

Pharmacological properties of *Astragalus membranaceus*

Oxidative stress reduction

The dried root extract of *Astragalus membranaceus* was found to inhibit the oxidative stress via the up-regulation of antioxidant factors i.e., keeping up the action of superoxide dismutase, reducing the formation of malondialdehyde and free radicals as well as diminishing cell apoptosis.^[6] Extracts of *Astragalus membranaceus* can inhibit the mechanism of oxidative stress via upregulating the antioxidant factors. In myocardial ischemic rat model, aqueous extract of *Astragalus membranaceus* reduced the myocardial infarction size and ameliorate the cardiac function via maintaining the level of superoxide dismutase, decreased the levels of lipid peroxidation and free radical generation, and reducing programmed cell death i.e apoptosis.^[7] In

Cite this article: Ikbal AMA, Rajkhowa A, Debnath B, Singh WS, Manna K, Bhattacharjee B, Das T, Goswami S. Pharmacological Review on *Astragalus membranaceus*: Chinese Traditional Herb. *Pharmacogn Rev.* 2022;16(32):90-4.



rat model of cerebral ischemia, treatment with *Astragalus membranaceus* can profoundly decreased the levels of malondialdehyde and reactive oxygen species via upregulating the expression of superoxide dismutase, glutathione peroxidase, catalase and nuclear factor erythroid 2-related factor 2.^[8] High cholesterol feeding in atherosclerotic rabbit model, treatment with *Astragalus flavonoids* reduced the plasma levels of low-density lipoprotein-cholesterol and total cholesterol, increased the high density lipoprotein-cholesterol levels and reduced the aortic fatty streak area.^[9] In PC12 cell lines models, isoflavonoids derived from *Astragalus membranaceus* including calycosin, formononetin shown neuronal protection via scavenging free radicals' generation in a dose dependent manner.^[10] *Astragalus* polysaccharide from *Astragalus membranaceus* shows protective antioxidant properties under *in-vitro* and *in-vivo* conditions.^[11,12] *Astragalus* polysaccharide increasing the levels of glutathione, superoxide dismutase, catalase, inhibit the formation of malondialdehyde.^[13] In mitochondria of mouse brain and liver, it was shown that treatment with *Astragalus* polysaccharide protects mitochondria from oxidative dysfunction, increased the activities of antioxidant enzymes.^[14]

Neuroprotective effect

The aqueous extract of dried roots of *Astragalus membranaceus* shown neuroprotective effect via reversing neurodegeneration and memory impairment. In a rat model, it can increase the number of muscarinic-cholinergic receptor in the cortex and hippocampus region.^[15] Additionally, treatment with aqueous extract of *Astragalus membranaceus* prevent the loss of synapses and axon in the hippocampus, and cortex and improved memory impairment.^[16] Astragalosides are cycloartone triterpenoid saponins derived from *Astragalus membranaceus* showed improved learning and memory in the Alzheimer's disease model via downregulating the expression of amyloid β (1-40), amyloid precursor protein, and β secretase in hippocampus regions of rats.^[17] Moreover, in cerebral ischemia rat model treatment with astragalosides improved the learning and memory abilities by improving the expression of p-ERK and p-Akt, decreasing the expression of p-JNK.^[18] An isoflavonoid derived from *Astragalus membranaceus*, formononetin protects the neurons and reduced the apoptotic cells activities by increasing the levels of procaspase-3 and Bcl-2 and decreasing the levels of caspase-3 and Bax.^[19] In the Parkinson's disease model induced by 6-hydroxydopamine, administration of astragalosides-IV prevents the loss and degeneration of dopaminergic neurons, increased the nitric oxide synthase levels of dopaminergic neurons and increased the number of tyrosine hydrolase immunopositive neurons.^[20]

Antiviral effects

The *Astragalus* polysaccharides could inhibit the reproductive capacity of herpes virus at a concentration of 30 μ g/mL which leads to a reduction in the occurrences of tumor.^[21] It has also been reported that the efficacy of foot and mouth disease virus (FMDV) vaccine can be significantly enhanced by utilizing 0.5mg of APS.^[21] APS have the potential to protect our body from viruses by inducing the production of interferons which further leads to the inhibition of viral reproduction.^[21] *In-vitro* study revealed that by reducing the levels of oxidative markers and activation of the necrosis factor- κ B signaling pathway, *Astragalus* polysaccharide inhibits the replication of porcine circovirus type 2.^[22] At a concentration of 30 μ g/mL, *Astragalus* polysaccharide significantly inhibits the expression of transcription activator and zipper transcription factor.^[23] Similarly, under *in-vitro* conditions *Astragalus* polysaccharide inhibits the replication of infectious bronchitis virus. After treatment with *Astragalus* polysaccharide, the levels of proinflammatory cytokines decrease, these results revealed that *Astragalus* polysaccharide had some activity against bronchitis virus.^[24]

Anticancer activity

It has been proven in various clinical studies that a traditional Chinese medicine formulation which comprised of *Astragalus*, significantly improved the therapeutic efficacy of chemotherapy.^[25] The stimulation of hematopoietic components as well as production of interleukins was found to be the most effective pathway for this formulation.^[25] It was also observed that the formulation comprising of *Astragalus* prevented the occurrence of malignancy thus, prolonging survival.^[25] This formulation is also capable of expanding the resistance to immunosuppression brought about by radiotherapy and antineoplastic medications through the stimulation of macrophages for formation of IL-6 as well as tumor necrosis factor.^[25] The extract of *Astragalus membranaceus* combined with anticancer drug, shown positive effect on the treatment of cancer.^[26] The hepatocellular carcinoma cell line HepG2, combination of aqueous extract of *Astragalus membranaceus* with *Salvia miltiorrhiza* could inhibit the invasion of tumor cells by modulating the expression of TGF-beta/Smad signaling.^[27] Another research work shown that in the hepatocellular carcinoma cell rat model induced by diethylnitrosamine, combination of aqueous extract of *Astragalus membranaceus* with *Salvia miltiorrhiza* could inhibit fibrosis and the transcription of plasminogen activator inhibitor-1 via reducing the incidence and multiplicity of hepatocellular carcinoma cell development in a dose dependent manner.^[28,29] In a time and dose dependent manner, aqueous extract of *Astragalus membranaceus* can inhibit the growth of human gastric cell lines AGS and KATO-III.^[30]

Astragalus membranaceus saponins can inhibit the spread of colon cancer and induce apoptosis. In colon cancer cells HCT116 and HT-29, *Astragalus membranaceus* saponins shown antineoplastic activity via modulating the expression of Akt/p13k/mTOR and ERK signaling pathway.^[31,32] Similarly, *Astragalus membranaceus* saponins hindered the cell cycle process at the G2/M phase through regulating p21, cmyc and cyclin B1 in human gastric adenocarcinoma cells.^[33] In a lung cancer mice model induced by indoleamine 2,3 dioxygenase, administration with astragalosides-IV inhibit the growth of tumor, interfered with T-cell immunity by decreasing Tregs.^[34] In breast cancer cell line MDA-MB-231, treatment with astragalosides-IV suppressed the cell viability and invasions of tumor cells, downregulated the expression of Vav3, MMP-2, and MMP-9 through suppressing the activation of ERK1/2 and JNK.^[35] In the hepatic cancer rat model induced by N-diethylnitrosamine, rhamnocitrin 4- β -D-galactopyranoside isolated from *Astragalus membranaceus* protects hepatocellular carcinogenesis by increasing the levels of antioxidant enzymes viz superoxide dismutase, glutathione peroxidase, glutathione-S-transferase, catalase and decreasing the level of lipid peroxidation.^[36,37] In HepG2 cell line, *Astragalus* polysaccharide inhibit the proliferation, arrest cell cycle in the G1 phase and induce apoptosis.^[38,39] In tumor bearing mice, treatment with *Astragalus* polysaccharide ameliorate proliferation and activity of intestinal intraepithelial γ δ T cells by increasing the levels of FasL, GrB and IFN- γ in γ δ T cells.^[40] In Kunming mice with Ehrlich's ascites carcinoma, *Astragalus* polysaccharide can inhibit the growth of tumor cells, decreasing the levels of CDK4 and Bcl-2, increased the percentage of CD³⁺ and CD⁴⁺ T-lymphocytes, the ratio of CD⁴⁺/ CD⁸⁺ T-cells and the expression of IL-2/IL-2R in spleen and Bax in tumor tissue.^[41]

Immunomodulatory effect

A study was conducted to observe the effects of total flavonoids in *Astragalus* on the macrophage-phagocytic index by utilizing the carbon clearance method.^[42] This study revealed that total flavonoids in concentrations of 25, 50 and 100mg/kg led to a significant increment in the phagocytosis of macrophages leading to commencement of mononuclear phagocytic framework of immune response against the

unfamiliar materials in our body.^[42] Lymphocyte proliferation plays a very crucial role in cellular and humoral resistance thus resulting in activation of a cascade of responses.^[43] Thus, the researchers conducted a study to evaluate the immunomodulatory activity of *Astragalus* polysaccharide-iron (III) complex by utilizing the lymphocyte proliferation method.^[43] The results of this study indicated that when the concentration of astragalus polysaccharide-iron (III) complex was 50µg/mL the lymphocyte proliferation expanded by 35.7% in contrast to that observed with *Astragalus* polysaccharide.^[43] The aqueous extract of *Astragalus membranaceus* also has significant role to promote immune function. In peripheral blood region of mononuclear cells, aqueous extract of *Astragalus membranaceus* induced migration and monocyte maturation.^[44]

In the macrophage cell line ANA-1 induced by advanced glycation end products, aqueous extract of *Astragalus membranaceus* inhibits the production of cytokine via arresting p38 MAPK and necrosis factor-κB signaling pathway.^[40,45] It was shown that the aqueous extract of *Astragalus membranaceus* activated CD⁴⁺ and CD⁸⁺ T-cells of humans without influencing proliferation.^[46,47] In the mouse macrophage cell line RAW264.7, *Astragalus* saponins can inhibit lipopolysaccharide induced inducible nitric oxide synthase and TNF-α expression via arresting p38MAPK/NF-κB signaling pathway.^[48] In mice primary splenocytes and T-cells, it was shown that astragalosides increased the phosphatase activity of CD45.^[49] Additionally, proliferation of T and B lymphocytes, and antibody production was increased by astragalosides-IV but suppressed the production of IL-1 and TNF-α from peritoneal macrophages.^[50] In HIV-infected patients, astragalosides-IV combined with cycloastragenol may upregulated the activity of telomerase, improved the proliferation and immune function of CD⁸⁺ T lymphocytes via activating Src/MEK/ERK pathway in a dose and time dependent manner.^[51] Also, astragalosides-IV profoundly inhibits the lipopolysaccharide and TNF-α induced expression of E-selectin and VCAM-1 via arresting the NF-κB pathway.^[52] In lipopolysaccharide stimulated RAW264.7 cells, it was revealed that formononetin, an isoflavonoids progressively inhibits the production of nitric oxide and the expression of inducible nitric oxide synthase and cyclooxygenase-2.^[53,54]

Vascular protective activity

It has been found that the *Astragalus* saponins are the chief bioactive constituents present in the roots of *Astragalus membranaceus*.^[55] The ability of *Astragalus* saponins to enhance the removal of free radicals and to significantly minimize lipid peroxidation is of utmost importance as the *Astragalus* saponins were found to have a protective effect against ischemia reperfusion injury.^[55] In the rat myocardial infarction model, treatment with astragalosides promotes angiogenesis via increasing the expression of VEGF and basic fibroblast growth factor.^[56] In acute myocardial infarction rat model, treatment with astragalosides-IV protects the cardiac function, reduced the infarct size and inhibit the left ventricular fibrosis.^[57] In neonatal rat primary cardiomyocytes, astragalosides-IV reduced the levels of malondialdehyde and reactive oxygen species by upregulating the glutathione peroxidase and superoxide dismutase activity.^[58,59] Moreover, astragalosides-IV can reduce the levels of inflammatory cytokines by downregulating the TLR4/necrosis factor-κB signaling pathway, upregulating sonic hedgehog pathway and the expression of TGF-β.^[60,61] In the human cardiac microvascular endothelial cells induced by Na₂S₂O₄, astragalus polysaccharide inhibits the cell apoptosis process via improving the levels of superoxide dismutase, Bcl-2, p13k/Akt, decreasing the levels of malondialdehyde, reactive oxygen species, and Bax and inhibiting the caspase-3 activity.^[62] In the high fat diet mouse, administration of astragalus polysaccharide reduces the levels of plasma cholesterol by upregulating the expression of low-density lipoprotein-receptor and cholesterol-7α-hydroxylase, increasing neutral sterol excretion and fecal bile acid, and inhibits the intestinal cholesterol absorption.^[63] In hind




Figure 1: Regulation of blood glucose levels by *Astragalus* polysaccharides.

limb ischemia rat models, intramuscularly administration of astragalus polysaccharide significantly increase the expression of VEGF, VEGFR-1, VEGFR-2, Ang-1, and Tie-2.^[64]

Antimicrobial activity

The *Astragalus* polysaccharides produced a dose-dependent bacteriostatic effect against pathogenic bacteria like *Streptococcus*, *Escherichia coli* and *Staphylococcus aureus*.^[65] It was also observed that the *Astragalus* polysaccharides could significantly inhibit the strains of *Staphylococcus aureus*, *Escherichia coli* and *Salmonella* when used in the concentrations of 20mg/L and 40mg/L.^[65] Silver nanoparticles were formed by utilizing the water-soluble part of polysaccharides obtained from the roots of *Astragalus membranaceus*.^[65] Further studies on the silver nanoparticles revealed that they were resistant to multi-drug resistant bacteria and thus have great potential for their removal from the body.^[65]

Antidiabetic activity

Recent studies conducted on the *Astragalus* polysaccharides (APS) have indicated that it significantly lessens the blood glucose, improves any conditions of insulin resistance and also helps in building up the sensitivity to insulin Figure 1.^[65] It was also observed to retard the apoptosis of β-cells of islet and thus, plays a crucial role in the remedy of diabetes mellitus.^[60,65] In non-obese diabetic mice, it was shown that *Astragalus* polysaccharides reduced the onset and incidence of type1 diabetes mellitus, reduced the inflammation of islet cells, and protects the structure of β cells.^[66] Similarly, administration of *Astragalus* polysaccharides (10 and 100 µg/mL) also stimulated the proliferation activity of MIN6 islet cells and decreased the apoptosis of cells. Therefore, improving the production of insulin and lowers the blood glucose levels.^[67] In type2 diabetes mellitus, it was shown that *Astragalus* polysaccharides can reduce the levels of blood glucose by reducing endoplasmic reticulum stress in patients, thereby increasing insulin sensitivity.^[68] Similarly, *Astragalus* polysaccharides can bind with and activate peroxisome proliferator-activated receptor γ, progressively inhibit hepatic glycosylation, and increased the nonoxidative metabolism of glucose in skeletal muscle.^[69] *Astragalus* polysaccharides also promotes cell differentiation, increased the expression of glucose transporter-4 mRNA in adipose tissue and adenosine monophosphate-activated protein kinase in liver tissue of type2 diabetes mellitus, decreased the expression of resistin mRNA and downregulates adipose tissue resistance protein in type2 diabetes rats.^[68,70]

CONCLUSION

The antioxidant property is due to the presence of *Astragalus* polysaccharide resulting in augmentation of the action of superoxide

dismutase causing decline of the apoptosis of cell because of declining generation of malondialdehyde and free radicals. Due to this property of antioxidant, utilization in myocardial infarction is greatly exploited. One of the prominent phytoconstituent called *Astragalus flavonoids* decreases the level of low-density lipoprotein-cholesterol in plasma reducing the risk of fatty plug accumulation in artery. This plant has shown excellent result in preventing degeneration of neurons because of the Astragalosides which are cycloartone triterpenoid saponins. Another phytoconstituent called formononetin which is a isoflavanoid which acts safeguarding in neurons. Astragalosides-IV which is a cycloartane-type triterpene glycoside acts in mitigating Parkinson's disease. *Astragalus polysaccharides* which is found in this plant acts as potent antiviral agent curbs the activation of transcription activator and zipper transcription factor. Traditional medicinal use of this plant is also involved in treatment of various types of carcinomas along with combating against immunosuppression after the patient undergoes radiotherapy and anticancer drugs because of presence of astragalosides-IV along with *Astragalus polysaccharide*. The former two phytoconstituents also plays an important role in modulating immune system of the body by upregulating and downregulating various biochemical constituents in our body. The *Astragalus polysaccharides* produced a dose-dependent bacteriostatic effect against pathogenic bacteria like *Streptococcus*, *Escherichia coli* and *Staphylococcus aureus*. It also possesses antihyperglycemic effect by lowering blood glucose levels.

ACKNOWLEDGEMENT

Tripura University (A Central University), Suryamaninagar, Tripura, India-799022, provided the authors with eresources.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ABBREVIATIONS

APS: Astragalus polysaccharides; **DN:** Diabetic nephropathy; **DCM:** Dilated cardiomyopathy.

REFERENCES

- Elujoba AA, Odeleye OM, Ogunyemi CM. Traditional medicine development for medical and dental primary health care delivery system in Africa. *Afr J Trad Compl Alt Med*. 2005;2(1):46-61. doi: 10.4314/ajtcam.v2i1.31103.
- Fu J, Wang Z, Huang L, Zheng S, Wang D, Chen S, et al. Review of the botanical characteristics, phytochemistry, and pharmacology of *Astragalus membranaceus* (Huangqi). *Phytother Res*. 2014;28(9):1275-83. doi: 10.1002/ptr.5188, PMID 25087616.
- Li M, Wang W, Xue J, Gu Y, Lin S (2011). Meta-analysis of the clinical value of *Astragalus membranaceus* in diabetic nephropathy. *J Ethnopharmacol*, 133, 412-419.
- Shahrajabian MH, Sun W, Cheng Q. *Astragalus*, an ancient medicinal root in traditional Chinese medicine, a gift from silk road. *Int J Agric Biol*. 2019;2019f, 3, 27-38.
- Agyemang K, Han L, Liu E, Zhang Y, Wang T, Gao X. Recent advances in *Astragalus membranaceus* anti-diabetic research: Pharmacological effects of its phytochemical constituents. *Evid Based Complement Alternat Med*. 2013;2013:654643. doi: 10.1155/2013/654643, PMID 24348714.
- Liu P, Zhao H, Luo Y. Anti-Aging Implications of *Astragalus membranaceus* (Huangqi): A Well-Known Chinese Tonic. *Aging Dis*. 2017;8(6):868-86. doi: 10.14336/AD.2017.0816, PMID 29344421 Page-868.
- Ma X, Zhang K, Li H, Han S, Ma Z, Tu P. Extracts from *Astragalus membranaceus* limit myocardial cell death and improve cardiac function in a rat model of myocardial ischemia. *J Ethnopharmacol*. 2013;149(3):720-8. doi: 10.1016/j.jep.2013.07.036, PMID 23968862.
- Cao J, Chen Z, Zhu Y, Li Y, Guo C, Gao K, et al. Huangqi-Honghua combination and its main components ameliorate cerebral infarction with Qi deficiency and blood stasis syndrome by antioxidant action in rats. *J Ethnopharmacol*. 2014;155(2):1053-60. doi: 10.1016/j.jep.2014.05.061, PMID 24960183.
- Wang D, Zhuang Y, Tian Y, Thomas GN, Ying M, Tomlinson B. Study of the effects of total flavonoids of *Astragalus* on atherosclerosis formation and potential mechanisms. *Oxid Med Cell Longev*. 2012;2012:282383. doi: 10.1155/2012/282383.
- Yu D, Duan Y, Bao Y, Wei C, An L. Isoflavonoids from *Astragalus mongholicus* protect PC12 cells from toxicity induced by L-glutamate. *J Ethnopharmacol*. 2005;98(1-2):89-94. doi: 10.1016/j.jep.2004.12.027, PMID 15763368.
- Li R, Chen W, Wang W, Tian W, Zhang X. Antioxidant activity of *Astragalus polysaccharides* and antitumor activity of the polysaccharides and siRNA. *Carbohydr Polym*. 2010;82(2):240-4. doi: 10.1016/j.carbpol.2010.02.048.
- Yan H, Xie Y, Sun S, Sun X, Ren F, Shi Q, et al. Chemical analysis of *Astragalus mongholicus polysaccharides* and antioxidant activity of the polysaccharides. *Carbohydr Polym*. 2010;82(3):636-40. doi: 10.1016/j.carbpol.2010.05.026.
- Jia R, Cao L, Xu P, Jeney G, Yin G. *In vitro* and *in vivo* hepatoprotective and antioxidant effects of *Astragalus polysaccharides* against carbon tetrachloride-induced hepatocyte damage in common carp (*Cyprinus carpio*). *Fish Physiol Biochem*. 2012;38(3):871-81. doi: 10.1007/s10695-011-9575-z, PMID 22089693.
- Li XT, Zhang YK, Kuang HX, Jin FX, Liu DW, Gao MB, et al. Mitochondrial protection and anti-aging activity of *Astragalus polysaccharides* and their potential mechanism. *Int J Mol Sci*. 2012;13(2):1747-61. doi: 10.3390/ijms13021747, PMID 22408421.
- Shi R, He L, Hu Y, Yi N, Weng S, Cao Y. The regulatory action of *Radix astragal* on M-cholinergic receptor of the brain of senile rats. *J Tradit Chin Med*. 2001;21(3):232-5. PMID 11789335.
- Tohda C, Tamura T, Matsuyama S, Komatsu K. Promotion of axonal maturation and prevention of memory loss in mice by extracts of *Astragalus mongholicus*. *Br J Pharmacol*. 2006;149(5):532-41. doi: 10.1038/sj.bjp.0706865, PMID 16981006.
- Li WZ, Wu WY, Huang DK, Yin YY, Kan HW, Wang X, et al. Protective effects of astragalosides on dexamethasone and Abeta25-35 induced learning and memory impairments due to decrease amyloid precursor protein expression in 12-month male rats. *Food Chem Toxicol*. 2012;50(6):1883-90. doi: 10.1016/j.fct.2012.03.064, PMID 22484447.
- Wu YY, Wu WY, Gong HL, Li WZ, Yin YY. Astragalosides attenuate learning and memory impairment in rats following ischemiareperfusion injury. *Mol Med Rep*. 2014;9(4):1319-24. doi: 10.3892/mmr.2014.1969, PMID 24567111.
- Tian Z, Liu SB, Wang YC, Li XQ, Zheng LH, Zhao MG. Neuroprotective effects of formononetin against NMDA-induced apoptosis in cortical neurons. *Phytother Res*. 2013;27(12):1770-5. doi: 10.1002/ptr.4928, PMID 23362211.
- Chan WS, Durairajan SS, Lu JH, Wang Y, Xie LX, Kum WF, et al. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture. *Neurochem Int*. 2009;55(6):414-22. doi: 10.1016/j.neuint.2009.04.012, PMID 19409437.
- Jia W, Junying J, Li S, Xue G, Jianping X, Min Y, et al. 2018. Extraction, structure and pharmacological activities of *astragalus polysaccharides*, applied sciences, Vol. 9. Issue-1 Page-122.
- Xue HX, Gan F, Zhang ZQ, Hu JF, Chen XX, Huang KH. *Astragalus polysaccharides* inhibits PCV2 replication by inhibiting oxidative stress and blocking NF- κ B pathway. *Int J Biol Macromol*. 2015;81:22-30. doi: 10.1016/j.ijbiomac.2015.07.050, PMID 26226456.
- Guo Q, Sun X, Zhang Z, Zhang L, Yao G, Li F, et al. The effect of *Astragalus polysaccharide* on the Epstein-Barr virus lytic cycle. *Acta Virol*. 2014;58(1):76-80. doi: 10.4149/av_2014_01_76, PMID 24717032.
- Zhang PJ, Liu XF, Liu HY, Wang WX, Liu XH, Li XT, et al. *Astragalus polysaccharides* inhibit avian infectious bronchitis virus infection by regulating viral replication. *Microb Pathog*. 2018;114:124-8. doi: 10.1016/j.micpath.2017.11.026, PMID 29170045.
- Auyeung KK, Han QB, Ko JK. *Astragalus membranaceus*: A review of its Protection against Inflammation and gastrointestinal Cancers. *Am J Chin Med*. 2016;44(1) Issue-01 Page: 1-22. doi: 10.1142/S0192415X16500014, PMID 26916911.
- Cho WC, Leung KN. *In vitro* and *in vivo* anti-tumor effects of *Astragalus membranaceus*. *Cancer Lett*. 2007;252(1):43-54. doi: 10.1016/j.canlet.2006.12.001, PMID 17223259.
- Liu X, Yang Y, Zhang X, Xu S, He S, Huang W, et al. Compound *Astragalus* and *Salvia miltiorrhiza* extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell. *J Gastroenterol Hepatol*. 2010;25(2):420-6. doi: 10.1111/j.1440-1746.2009.05981.x, PMID 19793165.
- Rui W, Xie L, Liu X, He S, Wu C, Zhang X, et al. Compound *Astragalus* and *Salvia miltiorrhiza* extract suppresses hepatocellular carcinoma progression by inhibiting fibrosis and PAI-1 mRNA transcription. *J Ethnopharmacol*. 2014;151(1):198-209. doi: 10.1016/j.jep.2013.10.022, PMID 24247078.
- Cui R, He J, Wang B, Zhang F, Chen G, Yin S, et al. Suppressive effect of *Astragalus membranaceus* Bunge on chemical hepatocarcinogenesis in rats. *Cancer Chemother Pharmacol*. 2003;51(1):75-80. doi: 10.1007/s00280-002-0532-5, PMID 12497209.
- Lin J, Dong HF, Oppenheim JJ, Howard OM. Effects of astragal radix on the growth of different cancer cell lines. *World J Gastroenterol*. 2003;9(4):670-3. doi: 10.3748/wjg.v9.i4.670, PMID 12679907.

31. Auyeung KK, Mok NL, Wong CM, Cho CH, Ko JK. *Astragalus* saponins modulate mTOR and ERK signaling to promote apoptosis through the extrinsic pathway in HT-29 colon cancer cells. *Int J Mol Med*. 2010;26(3):341-9. PMID 20664949.
32. Law PC, Auyeung KK, Chan LY, Ko JK. *Astragalus* saponins downregulate vascular endothelial growth factor under cobalt chloride-stimulated hypoxia in colon cancer cells. *BMC Complement Altern Med*. 2012;12:160. doi: 10.1186/1472-6882-12-160, PMID 22992293.
33. Auyeung KK, Woo PK, Law PC, Ko JK. *Astragalus* saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells. *J Ethnopharmacol*. 2012;141(2):635-41. doi: 10.1016/j.jep.2011.08.010, PMID 21864667.
34. Zhang A, Zheng Y, Que Z, Zhang L, Lin S, Le V, et al. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO. *J Cancer Res Clin Oncol*. 2014;140(11):1883-90. doi: 10.1007/s00432-014-1744-x, PMID 24980548.
35. Jiang K, Lu Q, Li Q, Ji Y, Chen W, Xue X. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. *Int Immunopharmacol*. 2017;42:195-202. doi: 10.1016/j.intimp.2016.10.001, PMID 27930970.
36. Saleem S, Shaharyar MA, Khusroo MJ, Ahmad P, Rahman RU, Ahmad K, et al. Anticancer potential of rhamnocitrin 4'-beta-D-galactopyranoside against N-diethylnitrosamine-induced hepatocellular carcinoma in rats. *Mol Cell Biochem*. 2013;384(1-2):147-53. doi: 10.1007/s11010-013-1792-6, PMID 24026428.
37. Kondeva-Burdina M, Krasteva I, Mitcheva M. Effects of rhamnocitrin 4-beta-D-galactopyranoside, isolated from *Astragalus hamosus* on toxicity models *in vitro*. *Pharmacogn Mag*. 2014;10(Suppl 3):S487-93. doi: 10.4103/0973-1296.139778, PMID 25298664.
38. Liu L, Zhang J, Li M, Zhang X, Zhang J, Li Z, et al. Inhibition of HepG2 cell proliferation by ursolic acid and polysaccharides via the downregulation of cyclooxygenase-2. *Mol Med Rep*. 2014;9(6):2505-11. doi: 10.3892/mmr.2014.2059, PMID 24638056.
39. Luo C, Urgard E, Voorder T, Metspalu A. The role of COX-2 and Nrf2/ARE in anti-inflammation and antioxidative stress: Aging and anti-aging. *Med Hypotheses*. 2011;77(2):174-8. doi: 10.1016/j.mehy.2011.04.002, PMID 21530094.
40. Sun S, Zheng K, Zhao H, Lu C, Liu B, Yu C, et al. Regulatory effect of astragalus polysaccharides on intestinal intraepithelial $\gamma\delta$ T cells of tumor bearing mice. *Molecules*. 2014;19(9):15224-36. doi: 10.3390/molecules190915224, PMID 25251192.
41. Li J, Bao Y, Lam W, Li W, Lu F, Zhu X, et al. Immunoregulatory and anti-tumor effects of polysaccharopeptide and *Astragalus* polysaccharides on tumor-bearing mice. *Immunopharmacol Immunotoxicol*. 2008;30(4):771-82. doi: 10.1080/08923970802279183, PMID 18686097.
42. Ze G, Hong-Yan X, Lu X, Sha-Sha W, Xue-Mei Z. *In-vivo* and *in-vitro* immunomodulatory and anti-inflammatory effects of total flavonoids of *astragalus*, Africa. *J Trad Complement Altern Med*. 2016;13 Issue-4 Page: 60-73.
43. Nan J, Huiru Q, Minghua Z, Qinghuan M, Qi L, Yuangang Z. Antioxidant, immunomodulatory, oxidative stress inhibitory and iron supplementation effect of *Astragalus membranaceus* polysaccharide-iron(III) complex on iron-deficiency anemia mouse model. *Int J Biol Mol*. 2019;132:213-21.
44. Denzler KL, Waters R, Jacobs BL, Rochon Y, Langland JO. Regulation of inflammatory gene expression in PBMCs by immunostimulatory botanicals. *PLOS ONE*. 2010;5(9):e12561. doi: 10.1371/journal.pone.0012561, PMID 20838436.
45. Qin Q, Niu J, Wang Z, Xu W, Qiao Z, Gu Y. *Astragalus membranaceus* inhibits inflammation via phospho-P38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)- κ B pathways in advanced glycation end product-stimulated macrophages. *Int J Mol Sci*. 2012;13(7):8379-87. doi: 10.3390/ijms13078379, PMID 22942709.
46. Zwickey H, Brush J, Iacullo CM, Connelly E, Gregory WL, Soumyanath A, et al. The effect of *Echinacea purpurea*, *Astragalus membranaceus* and *Glycyrrhiza glabra* on CD25 expression in humans: a pilot study. *Phytother Res*. 2007;21(11):1109-12. doi: 10.1002/ptr.2207, PMID 17661330.
47. Brush J, Mendenhall E, Guggenheim A, Chan T, Connelly E, Soumyanath A, et al. The effect of *Echinacea purpurea*, *Astragalus membranaceus* and *Glycyrrhiza glabra* on CD69 expression and immune cell activation in humans. *Phytother Res*. 2006;20(8):687-95. doi: 10.1002/ptr.1938, PMID 16807880.
48. Wang Y, Ren T, Zheng L, Chen H, Ko JK, Auyeung KK. *Astragalus* saponins inhibits lipopolysaccharide-induced inflammation in mouse macrophages. *Am J Chin Med*. 2016;44(3):579-93. doi: 10.1142/S0192415X16500324, PMID 27109155.
49. Wan CP, Gao LX, Hou LF, Yang XQ, He PL, Yang YF, et al. Astragaloside II triggers T cell activation through regulation of CD45 protein tyrosine phosphatase activity. *Acta Pharmacol Sin*. 2013;34(4):522-30. doi: 10.1038/aps.2012.208, PMID 23524573.
50. Wang YP, Li XY, Song CQ, Hu ZB. Effect of astragaloside IV on T, B lymphocyte proliferation and peritoneal macrophage function in mice. *Acta Pharmacol Sin*. 2002;23(3):263-6. PMID 11918853.
51. Yung LY, Lam WS, Ho MK, Hu Y, Ip FC, Pang H, et al. Astragaloside IV and cycloastragenol stimulate the phosphorylation of extracellular signal-regulated protein kinase in multiple cell types. *Planta Med*. 2012;78(2):115-21. doi: 10.1055/s-0031-1280346, PMID 22083896.
52. Zhang WJ, Hufnagl P, Binder BR, Wojta J. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-kappaB activation and adhesion molecule expression. *Thromb Haemost*. 2003;90(5):904-14. doi: 10.1160/TH03-03-0136, PMID 14597987.
53. Chen HJ, Chung CP, Chiang W, Lin YL. Anti-inflammatory effects and chemical study of a flavonoid-enriched fraction from adlay bran. *Food Chem*. 2011;126(4):1741-8. doi: 10.1016/j.foodchem.2010.12.074, PMID 25213953.
54. Lai PK, Chan JY, Cheng L, Lau CP, Han SQ, Leung PC, et al. Isolation of anti-inflammatory fractions and compounds from the root of *Astragalus membranaceus*. *Phytother Res*. 2013;27(4):581-7. doi: 10.1002/ptr.4759, PMID 22693074.
55. Li-Hong Q, Bi-Qi Z, Miao-Jun L, Xian-Ji X, Peng C. Vascular protective effects of *Astragalus membranaceus* and its main constituents in rats with chronic hyperhomocysteinemia. *Exp Ther Med*. 2017;14 Issue-3 Page: 2401-2407.
56. Yu JM, Zhang XB, Jiang W, Wang HD, Zhang YN. Astragalosides promote angiogenesis via vascular endothelial growth factor and basic fibroblast growth factor in a rat model of myocardial infarction. *Mol Med Rep*. 2015;12(5):6718-26. doi: 10.3892/mmr.2015.4307, PMID 26352430.
57. Cheng S, Yu P, Yang L, Shi H, He A, Chen H, et al. Astragaloside IV enhances cardioprotection of remote ischemic conditioning after acute myocardial infarction in rats. *Am J Transl Res*. 2016;8(11):4657-69. PMID 27904669.
58. Hu JY, Han J, Chu ZG, Song HP, Zhang DX, Zhang Q, et al. Astragaloside IV attenuates hypoxia-induced cardiomyocyte damage in rats by upregulating superoxide dismutase-1 levels. *Clin Exp Pharmacol Physiol*. 2009;36(4):351-7. doi: 10.1111/j.1440-1681.2008.05059.x, PMID 18986331.
59. Huang H, Lai S, Wan Q, Qi W, Liu J. Astragaloside IV protects cardiomyocytes from anoxia/reoxygenation injury by upregulating the expression of Hes1 protein. *Can J Physiol Pharmacol*. 2016;94(5):542-53. doi: 10.1139/cjpp-2015-0457, PMID 27070866.
60. Wang C, Li Y, Yang X, Bi S, Zhang Y, Han D, et al. Tetramethylpyrazine and Astragaloside IV synergistically ameliorate left ventricular remodeling and preserve cardiac function in a rat myocardial infarction model. *J Cardiovasc Pharmacol*. 2017;69(1):34-40. doi: 10.1097/FJC.0000000000000437, PMID 27676326.
61. Yang J, Wang HX, Zhang YJ, Yang YH, Lu ML, Zhang J, et al. Astragaloside IV attenuates inflammatory cytokines by inhibiting TLR4/NF- κ B signaling pathway in isoproterenol-induced myocardial hypertrophy. *J Ethnopharmacol*. 2013;150(3):1062-70. doi: 10.1016/j.jep.2013.10.017, PMID 24432369.
62. Xie L, Wu Y, Fan Z, Liu Y, Zeng J. *Astragalus* polysaccharide protects human cardiac microvascular endothelial cells from hypoxia/reoxygenation injury: The role of PI3K/AKT, Bax/Bcl-2 and caspase-3. *Mol Med Rep*. 2016;14(1):904-10. doi: 10.3892/mmr.2016.5296, PMID 27220872.
63. Cheng Y, Tang K, Wu S, Liu L, Qiang C, Lin X, et al. *Astragalus* polysaccharides lowers plasma cholesterol through mechanisms distinct from statins. *PLOS ONE*. 2011;6(11):e27437. doi: 10.1371/journal.pone.0027437, PMID 22110652.
64. Tu S, Shao A, Ren L, Chen T, Yao D. Angiogenesis effect of *Astragalus* polysaccharide combined with endothelial progenitor cells therapy in diabetic male rat following experimental hind limb ischemia. *Chin Med J (Engl)*. 2014;127(11):2121-8. PMID 24890165.
65. Zheng Y, Ren W, Zhang L, Zhang Y, Liu D, Liu Y. A review of the pharmacological action of *astragalus* polysaccharide. *Front Pharmacol*. 2020;11:349. doi: 10.3389/fphar.2020.00349, PMID 32265719.
66. Chen W, Yu MH, Li YM. Effects of astragalus polysaccharide on ultrastructure of pancreatic islet and expression of oxidative apoptosis factor in non-obesity diabetes mice. *Fudan Univ J Med Sci*. 2007;34:269-72.
67. Li L, Liu Y, Liu P, Li CL, Hu Y, Gu ZY, et al. Effects of *Astragalus* polysaccharide on Proliferation, Apoptosis and insulin Secretion of min 6 cells. *Chin J New Drugs*. 2011;20:2139-42.
68. Hu CH, Xu K, Sun J, Zhang XM, Liu X, Dang J. Effect of *Astragalus* polysaccharide on glucose and lipid metabolism in aged diabetic rats. *Chin J Gerontol*. 2018;38:1453-5.
69. Seino Y, Hirose H, Saito I, Itoh H. High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. *Metabolism*. 2007;56(11):1493-9. doi: 10.1016/j.metabol.2007.06.015, PMID 17950099.
70. Liu HF, Chen HJ, Wang GY, Han ZX, Zhang J. Effect of *Astragalus* polysaccharide on resistin Protein Expression in insulin resistant Rats with type 2 diabetes mellitus. *Food Nutr China*. 2012c;18:69-71.

Cite this article: Ikbal AMA, Rajkhowa A, Debnath B, Singh WS, Manna K, Bhattacharjee B, Das T, Goswami S. Pharmacological Review on *Astragalus membranaceus*: Chinese Traditional Herb. *Pharmacog Rev*. 2022;16(32):90-4.